[Significant decrease in quality of life in patients with pemphigus vulgaris. Results from the German Bullous Skin Disease (BSD) Study Group].

Dermatologische Klinik mit Poliklinik, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Germany.
Journal der Deutschen Dermatologischen Gesellschaft (Impact Factor: 1.4). 07/2005; 3(6):431-5. DOI: 10.1111/j.1610-0387.2005.05722.x
Source: PubMed

ABSTRACT Pemphigus vulgaris is a potentially life-threatening autoimmune disorder of the skin and mucous membranes characterized by antibodies against epidermal adhesion molecules. Clinically characteristic are painful chronic blisters or erosions of mucous membranes and skin. There are no published studies on the impact o this disease on quality of life.
This registration was performed within the scope of the German BSD (Bullous Skin Disease) study group, from November 1997 until January 2002. A total of 36 patients with the first diagnosis of pemphigus vulgaris were registered at the university hospitals of Dresden, Erlangen, Kiel, Mannheim, München and Würzburg. Thirty of the 36 (83 %) patients participated in the quality of life questionnaire utilizing the German version of 'Dermatology Life Quality Index' (DLQI) provided by A. Y. Finlay. The DLQI varies from 0 to 30 with an increased DLQI score indicating a decrease in quality of quality.
The overall DLQI total score of 10 +/- 6.7 in the investigated pemphigus patients was significantly increased in comparison to other skin diseases.
These results suggest that the DLQI can be a very useful additional outcome criteria for clinical studies with pemphigus vulgaris and in the treatment of these patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Genetic and acquired bullous dermatoses can severely affect multiple domains of a patient's quality of life (QOL). Integrating formal evaluation of QOL into the clinical evaluation of patients facilitates an objective assessment of disease severity, mapping of disease trajectory, and captures therapeutic intervention outcomes. There have been 5 studies evaluating QOL in autoimmune dermatoses and 4 studies reviewing QOL in the genodermatoses. All literature to date indicates a significant disease burden in this setting. The development of formal QOL instruments has facilitated quantification of QOL deficits in this arena and offers promising tools for patient assessment in the future.
    Clinics in dermatology 01/2012; 30(1):103-7. · 3.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pemphigus vulgaris and pemphigus foliaceus are rare, potentially life-threatening, autoimmune disorders characterized by antibodies to epidermal adhesion molecules. Clinical characteristics are painful chronic erosions of mucous membranes and of the skin. There are only few published studies on the impact of the disease on the health status (HS) of patients with these conditions. To assess the impact of disease on the HS of patients with pemphigus. Fifty-eight patients enrolled at the Bullous Skin Diseases Unit of IDI-IRCCS in the period January-June 2006 were assessed for their HS using the Medical Outcomes Study 36-item short form health survey (SF-36) questionnaire and for anxiety and depression using the Institute for Personality and Ability Testing questionnaires. A compromised HS on both the physical and the psychosocial scales was observed, similar to other chronic dermatological diseases such as psoriasis. Patients with anxiety had severe disease as measured by the Physician's Global Assessment and the degree of mucocutaneous involvement, as well as those with a more recent disease onset. A better HS was observed in patients whose clinical condition was rated as nonsevere, and also in patients with pemphigus foliaceus. In pemphigus vulgaris, antidesmoglein 3 antibody levels directly correlated with clinical severity and with lower SF-36 scores. HS evaluated with the SF-36 can be a very useful additional outcome criterion in clinical studies with pemphigus. The management of the disease must take into account its impact on various aspects of life of the patient.
    British Journal of Dermatology 06/2008; 158(5):1029-34. · 3.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Studies conducted using different tools, have invariably observed that physical and mental components of the health status were seriously compromised in patients with pemphigus. An improvement in quality of life (QoL) has been commonly observed over the treatment period. The aim of the study is to verify whether the patients' wellbeing is affected by pemphigus also in absence of cutaneous and mucosal lesions. The clinical records of 203 patients were analyzed. A total of 47 patients were without bullae/erosions and reported a score=0 for both the Patient Global Assessment and the Ikeda index. In order to assess the quality of life we used the Skindex-17 and the General Health Questionnaire-12 item questionnaires. Patients without bullae/erosions had a better quality of life when compared to the patients with active lesions. Such difference, with a reduction of approximately 30% of the Skindex-17 scores in the patients without lesions, was statistically significant, for both the symptoms and the psychosocial scales. The proportion of patients at risk of anxiety/depression (GHQ positives cases) was 44% lower in patients without lesions compared to patients with lesions. In a multiple linear regression model the presence of bullae/erosions negatively influences QoL with an average increase of Skindex -17 symptoms and psychosocial scale scores of 11.7 and 10.6 points, respectively. Females patients had a statistically significantly worse QoL than males on the symptoms but not on the psychosocial Skindex-17 scales. While patients without lesions reported a better quality of life than patients with bullae/erosions, their Skindex-17 scores remained elevated. Dermatologists should be aware that a clearing of the skin manifestations does not mean "perfect health" for the patient. This article is protected by copyright. All rights reserved.
    British Journal of Dermatology 01/2014; · 3.76 Impact Factor